Action Genmin - GEN

Genmin Limited (GEN) Action

Outils de qualité professionnelle, pour des investisseurs individuels.

Premium

Dernier

0,008

( - )

Prix Achat

0,007

Prix Vente

0,009

Volume échangé

252 052

0,008 Fourchette du Jour 0,008

0,005 Plage de 52 semaines 0,034

Cap du marché

27,676M

Clôture Veille

0,008

Ouverture

0,008

Dernière Transaction

52052

0.008

Dernière heure de transaction

Volume financier

VWAP

Volume moyen (3 m)

AUD 4 816 631

Actions en circulation

3 459 536 102

Rendement du Dividende (LTM)

Ratio Cours sur Bénéfices

-0,42

Bénéfice par action (BPA)

-0,01

Chiffre d'affairess (LTM)

Bénéfice net (LTM)

-14,15M

Genmin Limited, a mineral exploration and project development company, produces iron ore in Africa. Its flagship property comprises 100% owned project, the Baniaka iron ore located in south-east Gabon, west Central Africa. Genmin Limited was incorporated in 2010 and is based in West Perth, Australia... Genmin Limited, a mineral exploration and project development company, produces iron ore in Africa. Its flagship property comprises 100% owned project, the Baniaka iron ore located in south-east Gabon, west Central Africa. Genmin Limited was incorporated in 2010 and is based in West Perth, Australia. Show more

Secteur

Materials

Industrie

Mining

Site Web

www.genmingroup.com

Siège social

West Perth, Australia

Fondé

2026

Genmin Limited est coté dans le secteur Materials de la Australian Stock Exchange avec le ticker GEN. Le dernier cours de clôture d'Genmin était de AUD0,01. Au cours de la dernière année, les actions de Genmin ont été négociées dans une fourchette de prix de AUD 0,005 à AUD 0,034.

Genmin compte actuellement 3 459 536 102 actions en circulation. La capitalisation boursière d'Genmin est de AUD27,68 million. Genmin a un ratio cours/bénéfice (ratio PE) de -0.42.

Genmab Files IND for HuMax-TF-ADC

Company Announcement IND for HuMax(R)-TF-ADC submitted to FDA Genmab's first IND submission for antibody-drug conjugate (ADC) product...

Genentech and Biogen Idec Refused a Re-hearing of U.S. Court of Appeals Decision in the Arzerra Patent Infringement Case

Company Announcement Genentech and Biogen Idec refused re-hearing in Arzerra patent infringement case COPENHAGEN, Denmark, July 15, 2013...

Genmab Collaborator GSK Starts New Ofatumumab Phase III Study in Rare Skin Disorder

Company Announcement First Phase III study with subcutaneous formulation of ofatumumab Ofatumumab to be investigated in new autoimmune...

Genmab and ADC Therapeutics Enter Co-Development Collaboration for an Antibody-Drug Conjugate Combining HuMax-TAC and PBD Warhe

Media Release Antibody-drug conjugate (ADC) to be developed for cancer Combines strength of HuMax(R)-TAC with next generation...

Teprotumumab Restarts Clinical Development in New Indication

Company Announcement Teprotumumab (RG1507) to be investigated for new indication River Vision Development Corporation to conduct...

Genmab Launches Sponsored Level 1 American Depositary Receipt (ADR) Program

Company Announcement Genmab establishes Sponsored Level 1 ADR program Genmab ADRs can be traded on US over-the-counter (OTC) market...

GSK and Genmab Announce Positive Top-Line Results From Pivotal Study of ARZERRA(R) (ofatumumab) Combined With Chlorambucil in P

Company Announcement Median 22.4 month progression free survival in patients treated with ofatumumab plus chlorambucil, an improvement of...

Genentech and Biogen Idec Have Filed for a Re-hearing of U.S. Court of Appeals Decision in the Arzerra Patent Infringement Case

Company Announcement Genentech and Biogen Idec have filed for re-hearing in the United States COPENHAGEN, Denmark, May 17, 2013 (GLOBE...

Genmab Announces Financial Results for the First Quarter of 2013

COPENHAGEN, Denmark, May 7, 2013 (GLOBE NEWSWIRE) -- Interim Report First Quarter 2013 Arzerra(r) received approval in Japan Arzerra net...

Genmab Announces Top-Line Phase II Results for Ofatumumab Combined With Bendamustine in Untreated and Relapsed Chronic Lymphocy

Company Announcement 95% overall response rate and 43% complete response rate in patients with previously untreated chronic lymphocytic...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0.008	0.0085	0.008	1403442	0.00811691	DE
4	0.002	33.3333333333	0.006	0.009	0.006	4929390	0.00789544	DE
12	0.001	14.2857142857	0.007	0.009	0.005	4757909	0.00730297	DE
26	-0.001	-11.1111111111	0.009	0.01	0.005	6806910	0.00787446	DE
52	-0.018	-69.2307692308	0.026	0.034	0.005	4490152	0.00928434	DE
156	-0.127	-94.0740740741	0.135	0.2	0.005	2295171	0.01879348	DE
260	-0.207	-96.2790697674	0.215	0.28	0.005	1393641	0.02999945	DE

GEN - Frequently Asked Questions (FAQ)

What is the current Genmin Limited share price?

The current share price of Genmin Limited is AUD 0,008

How many Genmin Limited shares are in issue?

Genmin Limited has 3 459 536 102 shares in issue

What is the market cap of Genmin Limited?

The market capitalisation of Genmin Limited is AUD 27,68M

What is the 1 year trading range for Genmin Limited share price?

Genmin Limited has traded in the range of AUD 0,005 to AUD 0,034 during the past year

What is the PE ratio of Genmin Limited?

The price to earnings ratio of Genmin Limited is -0,42

What is the registered address of Genmin Limited?

The registered address for Genmin Limited is Suite 3, Level 1, West Perth, Western Australia, 6005

What is the Genmin Limited website address?

The website address for Genmin Limited is www.genmingroup.com

Which industry sector does Genmin Limited operate in?

Genmin Limited operates in the Mining sector

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Genmin Limited (GEN)

Genmin Limited (GEN) Action

Outils de qualité professionnelle, pour des investisseurs individuels.

Statistiques et détails clés

À propos de Genmin Limited

GEN Dernières nouvelles

Genmab Files IND for HuMax-TF-ADC

Genentech and Biogen Idec Refused a Re-hearing of U.S. Court of Appeals Decision in the Arzerra Patent Infringement Case

Genmab Collaborator GSK Starts New Ofatumumab Phase III Study in Rare Skin Disorder

Genmab and ADC Therapeutics Enter Co-Development Collaboration for an Antibody-Drug Conjugate Combining HuMax-TAC and PBD Warhe

Teprotumumab Restarts Clinical Development in New Indication

Genmab Launches Sponsored Level 1 American Depositary Receipt (ADR) Program

GSK and Genmab Announce Positive Top-Line Results From Pivotal Study of ARZERRA(R) (ofatumumab) Combined With Chlorambucil in P

Genentech and Biogen Idec Have Filed for a Re-hearing of U.S. Court of Appeals Decision in the Arzerra Patent Infringement Case

Genmab Announces Financial Results for the First Quarter of 2013

Genmab Announces Top-Line Phase II Results for Ofatumumab Combined With Bendamustine in Untreated and Relapsed Chronic Lymphocy

GEN - Frequently Asked Questions (FAQ)

GEN Transactions

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Genmin Limited (GEN)

Genmin Limited (GEN) Action

Outils de qualité professionnelle, pour des investisseurs individuels.

Statistiques et détails clés

À propos de Genmin Limited

GEN Dernières nouvelles

Genmab Files IND for HuMax-TF-ADC

Genentech and Biogen Idec Refused a Re-hearing of U.S. Court of Appeals Decision in the Arzerra Patent Infringement Case

Genmab Collaborator GSK Starts New Ofatumumab Phase III Study in Rare Skin Disorder

Genmab and ADC Therapeutics Enter Co-Development Collaboration for an Antibody-Drug Conjugate Combining HuMax-TAC and PBD Warhe

Teprotumumab Restarts Clinical Development in New Indication

Genmab Launches Sponsored Level 1 American Depositary Receipt (ADR) Program

GSK and Genmab Announce Positive Top-Line Results From Pivotal Study of ARZERRA(R) (ofatumumab) Combined With Chlorambucil in P

Genentech and Biogen Idec Have Filed for a Re-hearing of U.S. Court of Appeals Decision in the Arzerra Patent Infringement Case

Genmab Announces Financial Results for the First Quarter of 2013

Genmab Announces Top-Line Phase II Results for Ofatumumab Combined With Bendamustine in Untreated and Relapsed Chronic Lymphocy

GEN - Frequently Asked Questions (FAQ)

GEN Transactions

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Sign up for FREE and get:

Supprimer les publicités